Pharmaceutical Polymorphs

Polymorphism is a major concern for the pharmaceutical industry. Everything from efficacy to regulatory applications and intellectual property can be affected by a lack of polymorphic control over an API.

A recent paper by the Hall Group at the University of Bristol has highlighted a new technique for producing ‘disfavoured’ polymorphs (e.g. elusive paracetamol Form II), using “self-destructing” deep eutectic solvents. Mixing the crystallisation target with certain volatile solids produces a lower-boiling mixture which encourages metastable polymorphs to crystallise when the second component evaporates. A very interesting article, with implications throughout the pharmaceutical industry. The Chemistry World summary is here.

To learn more about how Crystec’s mSAS® (modified Supercritical Anti-Solvent) technology platform can be applied to control solid-state form to generate known and new (high pressure) polymorphs, check out our case study or get in touch!

To keep up to date with the latest news from Crystec, please follow us on LinkedIn.